Beer Tomasz M, Bubalo Joseph S
Division of Hematology and Medical Oncology, Oregon Health & Science University, Mail Code CR145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Urol Clin North Am. 2004 May;31(2):367-78. doi: 10.1016/j.ucl.2004.01.003.
Prevention and management of the adverse effects of prostate cancer chemotherapy depend on skilled regimen selection, dose adjustment, use of supportive care strategies, and a thorough understanding of the patient- and regimen-related factors that determine the risk for toxicity. Urologists, radiation oncologists, and primary care providers can play an important role before chemotherapy is prescribed by judicious use of treatments that impair bone marrow and other vital organ function. The current role of chemotherapy in prostate cancer is palliative. Successful palliation depends on reducing cancer-related suffering without introducing treatment-related suffering. Thus prevention and management of toxicity is central to the success of chemotherapy in advanced prostate cancer.
前列腺癌化疗不良反应的预防与管理取决于熟练的方案选择、剂量调整、支持性护理策略的使用,以及对决定毒性风险的患者相关因素和方案相关因素的透彻理解。在开具化疗处方之前,泌尿外科医生、放射肿瘤学家和初级保健提供者可以通过明智地使用会损害骨髓和其他重要器官功能的治疗方法发挥重要作用。化疗目前在前列腺癌中的作用是姑息性的。成功的姑息治疗取决于在不引入治疗相关痛苦的情况下减轻与癌症相关的痛苦。因此,毒性的预防和管理是晚期前列腺癌化疗成功的关键。